ABSORICA LD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Absorica Ld, and when can generic versions of Absorica Ld launch?
Absorica Ld is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has seventeen patent family members in nine countries.
The generic ingredient in ABSORICA LD is isotretinoin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Absorica Ld
A generic version of ABSORICA LD was approved as isotretinoin by AMNEAL PHARMS NY on September 29th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ABSORICA LD?
- What are the global sales for ABSORICA LD?
- What is Average Wholesale Price for ABSORICA LD?
Summary for ABSORICA LD
International Patents: | 17 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 10 |
Patent Applications: | 7,499 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ABSORICA LD |
DailyMed Link: | ABSORICA LD at DailyMed |
![ABSORICA LD drug patent expirations Drug patent expirations by year for ABSORICA LD](/p/graph/s/t/ABSORICA_LD-patent-expirations.png)
![Drug Prices for ABSORICA LD](/p/graph/drug-price/ABSORICA+LD.png)
Recent Clinical Trials for ABSORICA LD
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Oncology Group | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Sun Pharmaceutical Industries Limited | Phase 4 |
Pharmacology for ABSORICA LD
Drug Class | Retinoid |
US Patents and Regulatory Information for ABSORICA LD
ABSORICA LD is protected by two US patents.
Patents protecting ABSORICA LD
Oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Low dose oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-001 | Nov 5, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-004 | Nov 5, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-002 | Nov 5, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-006 | Nov 5, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ABSORICA LD
See the table below for patents covering ABSORICA LD around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 112017001963 | ⤷ Sign Up | |
South Africa | 201700843 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | ⤷ Sign Up |
Mexico | 2017004312 | COMPOSICION FARMACEUTICA ORAL DE BAJA DOSIS DE ISOTRETINOINA. (LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN.) | ⤷ Sign Up |
Mexico | 2017001331 | COMPOSICION FARMACEUTICA ORAL DE ISOTRETINOINA. (ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |